Myasthenia Gravis
NEJM 298:136, Drachman,D.B., 1978
Myasthenia Gravis, Study of Humoral Immune Mechanisms by Passive Transfer to Mice
NEJM 296:125, Toyka,K.V.,et al, 1977
Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice
Neurol 104:e213498, Zara,P.,et al, 2025
The "Chameleon Eyes Sign" in Myasthenia Gravis
Neurol 103:e209756, Zara,P.,et al, 2024
Clinicopathologic Conference, Myasthenia Gravis
NEJM 391:1441-1450, Case 32-2024, 2024
Clinicopathologic Conference, Brain Abscess Due to Infection with Listeria Monocytogeneses
NEJM 391:1529-1538, Case 33-2024, 2024
Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology
Ann Neurol 96:1020-1025, Falso,S.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Ocular Myasthenia Gravis, Central Ocular Motor Signs and Unilateral Visual Loss Caused by the Great Neuro-Ophthalmologic Impersonator
Neurol 102:e209260, Young,A. & Johnston,J.L., 2024
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Curtain Sign
NEJM 387:e7, Sherman, S.V., 2022
A 71-Year-Old Man Presenting with Acute Onset Dysarthria and Dysphagia
Neurol 96:180-184, Spagni, G.,et al, 2021
A 68-Year-Old Man with Proximal Weakness and Seizures
Neurol 97:e423-e428, Chen, T., 2021
Myasthenia Grais
www.mda.org, , 2021
Acetylcholine Receptor-Antibody-Positive Myasthenia Gravis Presenting with Early Atrophy and Nonfluctuating Weakness of Proximal Limb Muscles
J Clin Neurol 16:714-716, Pancheri, E.,et al, 2020
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Myasthenic Crisis Demanding Mechanical Ventilation
Neurol 94:e299-e313, Neumann, B.,et al, 2020
Long-Term Follow-Up, Quality of Life, and Survival of Patients with Lambert-Eaton Myasthenic Syndrome
Neurol 94:e511-e520, Lipka, A.F.,et al, 2020
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Useful Bedside Testing for Myasthenia Gravis
Neurol 94:e1870-e1871, Gomes del Carvalho Neto, E.,et al, 2020
Thymectomy for Myasthenia Gravis
Neurol 94:705-709, Gronseth, G.S.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
The Face of Myasthenia Gravis
Neurol 95:89-90, Ruiter, A.M.,et al, 2020
Ptosis that Resolves with Application of an Ice Pack
BMJ 369:m1147, Chakraborty, A. & Jacob, J., 2020
Drug Approved for Rare Muscle Weakening Syndrome
JAMA 321:239, Voelker, R., 2019
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
Bilateral Cavernous Carotid Aneurysms: Atypical Presentation of a Rare Cause of Mass Effect
Front Neurol doi:10.3389/fneur.2018.0069, Gagliardi, D.,et al, 2018
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
A Child with Arthrogryposis
Neurol 91:e995-e998, Irumudomom, O. & Ghosh, P.S., 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Congenital Myasthenic Syndromes in Adult Neurology Clinic
Neurol 91:e1770-e1777, Kao, J.C.,et al, 2018
A Child with Delayed Motor Milestones and Ptosis
Neurol 88:e158-e163, Ghosh, P.S., 2017
Dont Fall for Pseudo-INO
Neurol 88:e205-e206, Traber, G.L.et al, 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis
JAMA Neurol 74:60-66, Robeson, K.R.,et al, 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Mechanisms, Causes, and Effects of Hypercapnia
UptoDate Dec, Feller-Kopman, D.J. & Schwartzstein, R.M., 2016
Myasthenia Gravis Exacerbation after Discontinuing Mycophenolate
Neurol 86:1159-1163, Oskarsson, B.,et al, 2016
Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation
JAMA Neurol 73:652-658,624, Bryant, A.,et al, 2016
A Randomized Controlled Trial of Methotrexate for Patients with Generalized Myasthenia Gravis
Neurol 87:57-64, Pasnoor, M.,et al, 2016
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Randomized Trial of Thymectomy in Myasthenia Gravis
NEJM 375:511-522,576, Wolfe, G.I.,et al, 2016
Clinical Manifestations of Myasthenia Gravis
UptoDate Aug 2016, Bird, S.J., 2016
Myasthenia Gravis after Botulinum Toxin Type A Injection
Turk J Neurol 22:143-144, Tekce, H.D.,et al, 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016